

# CITATION REPORT

List of articles citing

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra) in Chinese healthy subjects

DOI: 10.1080/07853890.2021.1887925  
Annals of Medicine, 2021, 53, 375-383.

**Source:** <https://exaly.com/paper-pdf/78748203/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.. <i>Expert Review of Clinical Immunology</i> , <b>2022</b> ,	5.1	2
3	Current status and prospects of IL-6 targeting therapy. <i>Expert Review of Clinical Pharmacology</i> , 1-18	3.8	1
2	Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.		0
1	Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose escalation study. <b>2023</b> , 32, 161-170		0